Eric Padron, MD
Medical Oncology · Tampa, FLNPI 1003904889
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $37,572 of the $54,339 with a category attached, or 69.1%. 10 manufacturers reported payments, led by Novartis at 32.7% of the total. Reporting peaked in 2020 at $17,981 and has fallen 67.5% since, to $5,849 in 2025.
Across 40 payments — averaging $1358.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$18K
- Blueprint Medicines Corporation$11K
- Taiho Oncology, Inc.$9K
- GSK$7K
- Geron Corporation$5K
- CTI Biopharma Corp.$3K
- plus $2K from 4 others
Across 49 payments — averaging $31,599 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$1.4M
- Bristol Myers Squibb$147K
What the payments were for
- Consulting fees$14,41127%
- Speaking & faculty fees$37,57269%
- Travel & lodging$1,5243%
- Food & beverage$8332%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $17,781 |
| Blueprint Medicines Corporation | 9 | $10,891 |
| Taiho Oncology, Inc. | 7 | $9,466 |
| GSK | 1 | $6,500 |
| Geron Corporation | 2 | $4,631 |
| CTI Biopharma Corp. | 1 | $3,080 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,186 |
| AbbVie | 1 | $675 |
| Bristol Myers Squibb | 1 | $96 |
| Sobi, Inc | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,339 in reported general payments places this provider in the 85th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IdhifaEnasidenib Mesylate | 16 | $538,472 |
| OjjaaraMomelotinib Dihydrochloride | 16 | $439,421 |
| JakafiRuxolitinib Phosphate | 16 | $415,355 |
| VenclextaVenetoclax | 15 | $42,307 |
| PegasysPeginterferon Alfa-2a | 15 | $32,863 |
| Hydroxyurea | 26 | $536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbIdhifa | $96 | $538,47216 claims |
| GSKOjjaara | $6,500 | $439,42116 claims |
| AbbVieVenclexta | $675 | $42,30715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Tampa
- Eduardo SotomayorTampa$362K
- Kenneth ShainTampa$341K
- Ivan BorrelloTampa$336K
- Alberto ChiapporiTampa$325K
- Jingsong ZhangTampa$220K
- Sameh GaballaTampa$214K
- Adil DaudTampa$204K
- Jeffrey WeberTampa$193K
- Mayer FishmanTampa$193K
- Jonathan StrosbergTampa$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.